Carboplatin and Etoposide in an Out-Patient Schedule for the Palliation of Advanced Non-Small-Cell Lung Cancer

Enrico Aitini, F Smerieri, Maurizio Cantore, Stefano Fazion(Azienda Ospedaliera Carlo Poma), Carla Rabbi, Andrea Mambrini, Riccardo Malaspina(Medica (Italy)), Riccardo Truzzi(Azienda Ospedaliera Carlo Poma), Franco Natale, Franca Pari, Giovanna Cavazzini(University of Padua), Marcello Amadori(Medica (Italy)), D. Zamagni

Tumori Journal

November 1, 1995

10.1177/030089169508100608

Cited by 6

Related Papers

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

|The Lancet Oncology|2020|322

Trends and challenges in the operation of pumped-storage hydropower plants

|Renewable and Sustainable Energy Reviews|2015|315

A new generation of small hydro and pumped-hydro power plants: Advances and future challenges

|Renewable and Sustainable Energy Reviews|2014|273

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

|The Lancet|2015|202

A PSO (particle swarm optimization)-based model for the optimal management of a small PV(Photovoltaic)-pump hydro energy storage in a rural dry area

|Energy|2014|170